Astrana Health, Inc. (NASDAQ:ASTH) Receives $34.00 Consensus Price Target from Analysts

Astrana Health, Inc. (NASDAQ:ASTH) has received an average recommendation of “Moderate Buy” from the eight ratings firms that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $34.00.

A number of brokerages have commented on ASTH. Zacks Research upgraded Astrana Health from a “strong sell” rating to a “hold” rating in a research report on Wednesday, March 11th. Truist Financial boosted their target price on Astrana Health from $37.00 to $38.00 and gave the stock a “buy” rating in a research report on Friday, March 13th. BTIG Research cut their price target on Astrana Health from $45.00 to $40.00 and set a “buy” rating on the stock in a research note on Monday, February 2nd. Needham & Company LLC initiated coverage on Astrana Health in a report on Friday, December 12th. They issued a “buy” rating and a $28.00 price target on the stock. Finally, Weiss Ratings reiterated a “sell (d+)” rating on shares of Astrana Health in a research report on Monday, December 29th.

Astrana Health Price Performance

Shares of ASTH stock opened at $24.19 on Friday. Astrana Health has a 1 year low of $18.08 and a 1 year high of $34.80. The company has a current ratio of 1.40, a quick ratio of 1.40 and a debt-to-equity ratio of 1.25. The firm’s 50 day moving average is $22.79 and its 200-day moving average is $25.50. The firm has a market capitalization of $1.34 billion, a price-to-earnings ratio of 52.59 and a beta of 0.91.

Astrana Health (NASDAQ:ASTH) last issued its quarterly earnings results on Monday, March 2nd. The company reported $0.54 earnings per share for the quarter, beating analysts’ consensus estimates of $0.15 by $0.39. Astrana Health had a net margin of 0.71% and a return on equity of 5.59%. The business had revenue of $950.53 million during the quarter, compared to analyst estimates of $930.46 million. During the same quarter last year, the business posted ($0.15) earnings per share. Astrana Health’s revenue for the quarter was up 42.9% compared to the same quarter last year. Sell-side analysts forecast that Astrana Health will post 1.15 EPS for the current fiscal year.

Institutional Investors Weigh In On Astrana Health

Several institutional investors have recently modified their holdings of the business. Royal Bank of Canada raised its stake in shares of Astrana Health by 6.5% during the first quarter. Royal Bank of Canada now owns 278,619 shares of the company’s stock worth $8,640,000 after buying an additional 17,028 shares during the last quarter. AQR Capital Management LLC bought a new position in Astrana Health in the first quarter valued at approximately $933,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Astrana Health by 5.2% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 25,768 shares of the company’s stock valued at $799,000 after acquiring an additional 1,263 shares during the last quarter. Jones Financial Companies Lllp grew its holdings in Astrana Health by 4,365.2% during the 1st quarter. Jones Financial Companies Lllp now owns 11,163 shares of the company’s stock worth $346,000 after acquiring an additional 10,913 shares during the period. Finally, Intech Investment Management LLC grew its holdings in Astrana Health by 5.8% during the 1st quarter. Intech Investment Management LLC now owns 44,586 shares of the company’s stock worth $1,383,000 after acquiring an additional 2,462 shares during the period. Institutional investors and hedge funds own 52.77% of the company’s stock.

About Astrana Health

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients. It offers care coordination services to patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans.